Suppr超能文献

胆固醇:有之害之,无之亦害。

Cholesterol: Can't Live With It, Can't Live Without It.

作者信息

Pownall Henry J, Gotto Antonio M

机构信息

HOUSTON METHODIST RESEARCH INSTITUTE, HOUSTON, TEXAS; WEILL CORNELL MEDICINE, NEW YORK, NEW YORK.

出版信息

Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):9-15. doi: 10.14797/mdcj-15-1-9.

Abstract

Given its role in many biochemical processes essential to life, cholesterol remains a topic of intense research. Of all the plasma lipids, cholesterol is distinctive because it is a precursor to steroidogenic molecules, some of which regulate metabolism, and its blood concentration in the form of low- and high-density lipoprotein cholesterol (HDL-C) are positive and negative risk factors for atherosclerotic cardiovascular disease (ASCVD). New research, however, has challenged the widely held belief that high HDL-C levels are atheroprotective and is showing that both low and high plasma HDL-C levels confer an increased risk of ASCVD. Furthermore, it is disputing the widely cited mechanism involved in reverse cholesterol transport. This review explores the evolution of cholesterol research starting with the Gofman and Framingham studies, the development of traditional and emerging lipid-lowering therapies, and the role of reverse cholesterol transport in HDL cardioprotection.

摘要

鉴于胆固醇在许多生命必需的生化过程中所起的作用,它仍然是一个深入研究的课题。在所有血浆脂质中,胆固醇具有独特性,因为它是类固醇生成分子的前体,其中一些分子调节新陈代谢,并且其以低密度和高密度脂蛋白胆固醇(HDL-C)形式存在的血液浓度分别是动脉粥样硬化性心血管疾病(ASCVD)的正性和负性危险因素。然而,新的研究对广泛持有的高HDL-C水平具有抗动脉粥样硬化保护作用这一观点提出了挑战,并表明血浆HDL-C水平无论是低还是高都会增加ASCVD的风险。此外,它还对广泛引用的胆固醇逆向转运机制提出了质疑。本综述探讨了从戈夫曼和弗雷明汉姆研究开始的胆固醇研究的演变、传统和新兴降脂疗法的发展以及胆固醇逆向转运在HDL心脏保护中的作用。

相似文献

1
Cholesterol: Can't Live With It, Can't Live Without It.
Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):9-15. doi: 10.14797/mdcj-15-1-9.
2
[HDL and CETP in atherogenesis].
Dtsch Med Wochenschr. 2010 Feb;135(5):188-92. doi: 10.1055/s-0030-1247862. Epub 2010 Jan 15.
3
Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c.
Eur J Clin Invest. 2009 Aug;39(8):680-8. doi: 10.1111/j.1365-2362.2009.02155.x. Epub 2009 May 12.
4
HDL-C: role as a risk modifier.
Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6.
5
High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.
Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):32-40. doi: 10.1016/j.pcad.2015.05.004. Epub 2015 May 9.
6
Pitavastatin: novel effects on lipid parameters.
Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X.
7
Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances In reverse Cholesterol Transport.
Ann Hepatol. 2017 Nov;16(Suppl. 1: s3-105.):s27-s42. doi: 10.5604/01.3001.0010.5495.
9
High-density lipoprotein: is it always atheroprotective?
Curr Atheroscler Rep. 2006 Sep;8(5):405-11. doi: 10.1007/s11883-006-0038-4.
10
High-Density Lipoprotein Processing and Premature Cardiovascular Disease.
Methodist Debakey Cardiovasc J. 2015 Jul-Sep;11(3):181-5. doi: 10.14797/mdcj-11-3-181.

引用本文的文献

1
Inhibition of post-lanosterol biosynthesis by fentanyl: potential implications for Fetal Fentanyl Syndrome (FFS).
Mol Psychiatry. 2024 Dec;29(12):3942-3949. doi: 10.1038/s41380-024-02622-5. Epub 2024 Jun 6.
2
The pathophysiology of excess plasma-free cholesterol.
Curr Opin Lipidol. 2023 Dec 1;34(6):278-286. doi: 10.1097/MOL.0000000000000899. Epub 2023 Sep 25.
3
Current Insights on Dyslipidaemia Management for Prevention of Atherosclerotic Cardiovascular Disease: A Malaysian Perspective.
Malays J Med Sci. 2023 Feb;30(1):67-81. doi: 10.21315/mjms2023.30.1.6. Epub 2023 Feb 28.
4
HDL and Lipid Metabolism.
Adv Exp Med Biol. 2022;1377:49-61. doi: 10.1007/978-981-19-1592-5_4.
5
Centrality of Myeloid-Lineage Phagocytes in Particle-Triggered Inflammation and Autoimmunity.
Front Toxicol. 2021 Nov 4;3:777768. doi: 10.3389/ftox.2021.777768. eCollection 2021.

本文引用的文献

3
Is It Time for New Thinking About High-Density Lipoprotein?
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):484-486. doi: 10.1161/ATVBAHA.118.310727.
4
High-Density Lipoprotein Cholesterol and Mortality: Too Much of a Good Thing?
Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):669-672. doi: 10.1161/ATVBAHA.117.310587. Epub 2018 Jan 11.
5
ABCA1-Derived Nascent High-Density Lipoprotein-Apolipoprotein AI and Lipids Metabolically Segregate.
Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2260-2270. doi: 10.1161/ATVBAHA.117.310290. Epub 2017 Oct 26.
6
CETP inhibition improves the lipid profile but has no effect on clinical cardiovascular outcomes in high-risk patients.
Evid Based Med. 2017 Oct;22(5):184-185. doi: 10.1136/ebmed-2017-110791. Epub 2017 Aug 26.
8
10
High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans.
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1784-1793. doi: 10.2215/CJN.00730116. Epub 2016 Aug 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验